Funding for this research was provided by:
EkstraStiftelsen Helse og Rehabilitering (2015/FO6336)
Helse Vest (912069)
Helse Sør-Øst RHF
Meso Scale Diagnostics
Text and Data Mining valid from 2018-07-13
Received: 9 March 2018
Accepted: 28 May 2018
First Online: 13 July 2018
Ethics approval and consent to participate
: The protocol for the ARCTIC trial was approved by the local ethics committee of the South-Eastern Norway Regional Health Authority (2010/744) and the study was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. All patients provided written informed consent.
: MKJ reports grants from Norwegian Extra Foundation for Health and Rehabilitation and the Western Norway Regional Health Authority. AHH: none. MH: none. ABA: none. JS: none. LMA is an employee of Thermo Fisher Scientific. MC: none. GS is co-inventor of several international patents for ACPA antigens held by BioMérieux Cy and licensed to Eurodiagnostica Cy and Axis-Shield Cy for commercialization of the CCP2 assays; according to French law he receives a part of the royalties paid to the Toulouse III University and the University Hospital of Toulouse. SL: none. BTSF: none. AIC: none. EAH has received investigator-initiated grants from AbbVie, Pfizer, MSD, UCB Pharma and Roche.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.